Product Description
A small molecule (GIM-407) that simultaneously enhances the quantity and function of Tregs. This approach sets the stage for a first-in-class immunotherapeutic to target Tregs in a wide number of autoimmune conditions. (Sourced from: https://www.georgiamune.com/pipeline)
Mechanisms of Action: T-Reg Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Georgiamune Inc
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|